Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer
Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research.